Disposition of orally administered atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor in healthy participants

Autor: Xue‐Qing Li, Bo Lindmark, Carl Amilon, Kristin Samuelsson, Lars Weidolf, Karin Nelander, Jane Knöchel, Maria Heijer, Ryan A. Bragg, Malin Gränfors, Eva‐Lotte Lindstedt, Sharan Sidhu, Pavlo Garkaviy, Hans Ericsson

Publikováno v: Pharmacology Research & Perspectives, Vol 12, Iss 5, Pp n/a-n/a (2024)

Abstract In this study, the mass balance, pharmacokinetics (PK) and metabolism of atuliflapon, a novel 5‐lipoxygenase‐activating protein inhibitor, were investigated in healthy male subjects. A single oral dose of 200 mg [14C]atuliflapon suspensi

Externí odkaz: https://doaj.org/article/76c37c93a11c42119bf483510f8f49aa

Application of Accelerator Mass Spectrometry to Characterize the Mass Balance Recovery and Disposition of AZD4831, a Novel Myeloperoxidase Inhibitor, following Administration of an Oral Radiolabeled Microtracer Dose in Humans

Autor: Chandrali Bhattacharya, Ann-Sofie Sandinge, Ryan A. Bragg, Maria Heijer, Jingjing Yan, Linda C. Andersson, Ulrik Jurva, Marta Pelay-Gimeno, Wouter H.J. Vaes, Rianne A.F. de Ligt, Malin Gränfors, Carl Amilon, Eva-Lotte Lindstedt, Somasekhara R. Menakuru, Pavlo Garkaviy, Lars Weidolf, V. Sashi Gopaul

Publikováno v: Drug Metabolism and Disposition. 51:451-463

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e32d1617b5bd8c510ddc429b7c85fe93
https://doi.org/10.1124/dmd.122.001100

Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD

Autor: Konstantina Psachoulia, Eva-Lotte Lindstedt, Carl Whatling, Gordon Law, Iain MacPhee, Hans Ericsson, Hiddo J.L. Heerspink, Kathleen Connolly, Jane Knöchel

Publikováno v: Kidney International Reports
Kidney International Reports, 6(11), 2803-2810. ELSEVIER SCIENCE INC

Introduction Patients with chronic kidney disease (CKD) remain at risk for kidney and cardiovascular events resulting from residual albuminuria, despite available treatments. Leukotrienes are proinflammatory and vasoconstrictive lipid mediators impli

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00d90929092531daac9f96fa967e930d
https://doi.org/10.1016/j.ekir.2021.08.018

Myeloperoxidase inhibition decreases morbidity and oxidative stress in mice with cystic fibrosis-like lung inflammation

Autor: Brian J. Day, Anthony J. Kettle, Erik Michaëlsson, Nina Dickerhof, John F. Pearson, Eva-Lotte Lindstedt, Jie Huang, Elysia Min

Publikováno v: Free Radical Biology and Medicine. 152:91-99

Cystic fibrosis (CF) lung disease is characterized by severe bacterial infections, excessive neutrophilic inflammation and oxidative stress. The neutrophil enzyme myeloperoxidase (MPO), which produces hypochlorous acid, is associated with worse disea

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b844ffcdd90dd1829b4f9b558cc59b8
https://doi.org/10.1016/j.freeradbiomed.2020.03.001

Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction : The phase 2a FLAVOUR study

Autor: Eva Prescott, Oskar Angerås, David Erlinge, Erik L. Grove, Marja Hedman, Lisette O. Jensen, John Pernow, Antti Saraste, Axel Åkerblom, Sara Svedlund, Anna Rudvik, Jane Knöchel, Eva-Lotte Lindstedt, Pavlo Garkaviy, Li-Ming Gan, Anders Gabrielsen

Publikováno v: Prescott, E, Angerås, O, Erlinge, D, Grove, E L, Hedman, M, Jensen, L O, Pernow, J, Saraste, A, Åkerblom, A, Svedlund, S, Rudvik, A, Knöchel, J, Lindstedt, E-L, Garkaviy, P, Gan, L-M & Gabrielsen, A 2022, ' Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction : The phase 2a FLAVOUR study ', International Journal of Cardiology, vol. 365, pp. 34-40 . https://doi.org/10.1016/j.ijcard.2022.07.016
Prescott, E, Angerås, O, Erlinge, D, Grove, E L, Hedman, M, Jensen, L O, Pernow, J, Saraste, A, Åkerblom, A, Svedlund, S, Rudvik, A, Knöchel, J, Lindstedt, E L, Garkaviy, P, Gan, L M & Gabrielsen, A 2022, ' Safety and efficacy of the 5-lipoxygenase-activating protein inhibitor AZD5718 in patients with recent myocardial infarction : The phase 2a FLAVOUR study ', International Journal of Cardiology, vol. 365, pp. 34-40 . https://doi.org/10.1016/j.ijcard.2022.07.016

Background: Leukotrienes are pro-inflammatory vasoactive lipid mediators implicated in the pathophysiology of atherosclerotic cardiovascular disease. We studied the effect of the 5-lipoxygenase-activating protein inhibitor AZD5718 on leukotriene bios

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d672ae6b861fe174ef48b19478c1ed6b
http://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-486108